• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Oragenics Inc (NY: OGEN )

    0.3140 UNCHANGED
    Streaming Delayed Price Updated: 8:00 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Oragenics Inc

    < Previous 1 2 Next >
    BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Oragenics to Present at Centurion One Capital 2nd Annual Bahamas Summit
    Via Investor Brand Network
    BioMedNewsBreaks — Oragenics, Inc. (NYSE American: OGEN) Reports on Lead Candidate Drug Development, ‘Urgency’ to Advance First-in-Class Concussion Treatment
    Via Investor Brand Network
    Exposures Product Safety
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Advances Concussion Treatment with Promising Study for Nasal Spray Drug ONP-002
    Via Investor Brand Network
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Closes on $4.45M Public Offering
    Via Investor Brand Network
    BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Enters into Public Offering Agreement Estimated to Total $4.45M
    Via Investor Brand Network
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Completes Manufacture, Filling of Intranasal Device for Use in Upcoming Clinical Trial
    Via Investor Brand Network
    BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion
    Via Investor Brand Network
    Exposures Product Safety
    “Explosive Growth Stocks: Innovations, Strategy, Earners Unlock Prime Potential CXAI, OGEN, PRSO, INBS, KAVL”
    Via AB Newswire
    Topics Artificial Intelligence
    Exposures Artificial Intelligence Product Safety
    As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
    EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
    From Oragenics, Inc.
    Via Business Wire
    Oragenics, Inc. Files 10K and Provides Company Update
    From Oragenics, Inc.
    Via Business Wire
    Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
    From Oragenics, Inc.
    Via Business Wire
    Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
    From Oragenics, Inc.
    Via Business Wire
    Oragenics Announces Closing of Public Offering
    From Oragenics, Inc.
    Via Business Wire
    Oragenics Announces Pricing of Public Offering
    From Oragenics, Inc.
    Via Business Wire
    Oragenics Announces Proposed Public Offering
    From Oragenics, Inc.
    Via Business Wire
    Oragenics, Inc. Announces Leadership Transition
    From Oragenics, Inc.
    Via Business Wire
    Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
    From Oragenics, Inc.
    Via Business Wire
    Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
    From Oragenics, Inc.
    Via Business Wire
    Oragenics Announces Termination of At-The-Market Offering Program
    From Oragenics, Inc.
    Via Business Wire
    Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
    From Oragenics, Inc.
    Via Business Wire
    Oragenics Issues Update to Shareholders
    From Oragenics
    Via Business Wire
    Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors
    From Oragenics, Inc.
    Via Business Wire
    Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
    From Oragenics, Inc.
    Via Business Wire
    Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets
    From Oragenics, Inc.
    Via Business Wire
    Oragenics, Inc. Announces Private Placement
    From Oragenics, Inc.
    Via Business Wire
    Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
    From Oragenics, Inc.
    Via Business Wire
    Oragenics to Participate in the World Vaccine Congress Washington
    From Oragenics, Inc.
    Via Business Wire
    Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
    From Oragenics, Inc.
    Via Business Wire
    Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team
    From Oragenics, Inc.
    Via Business Wire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.